

# Jeff Szer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/853259/publications.pdf>

Version: 2024-02-01

366  
papers

15,630  
citations

23567

58  
h-index

20961

115  
g-index

372  
all docs

372  
docs citations

372  
times ranked

13494  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2006, 355, 1233-1243.	27.0	1,060
2	Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. <i>Lancet, The</i> , 1992, 339, 640-644.	13.7	872
3	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. <i>Blood</i> , 2003, 102, 276-283.	1.4	707
4	Hematopoietic Stem Cell Transplantation&lt;sub>title&gt;A Global Perspective&lt;/sub>. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1617.	7.4	556
5	Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2007, 110, 4123-4128.	1.4	481
6	Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1800-1810.	27.0	455
7	A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2013, 368, 1771-1780.	27.0	384
8	One million haemopoietic stem-cell transplants: a retrospective observational study. <i>Lancet Haematology,the</i> , 2015, 2, e91-e100.	4.6	329
9	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 348-371.	2.0	324
10	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2013, 162, 62-73.	2.5	320
11	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i> , 2012, 120, 1570-1580.	1.4	268
12	Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. <i>Bone Marrow Transplantation</i> , 2016, 51, 778-785.	2.4	259
13	Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. <i>Blood</i> , 2002, 100, 761-767.	1.4	258
14	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. <i>Blood</i> , 2019, 133, 540-549.	1.4	239
15	Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. <i>Blood</i> , 2001, 98, 1732-1738.	1.4	228
16	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. <i>Blood</i> , 2006, 108, 88-96.	1.4	226
17	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	1.4	210
18	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 109-133.	0.7	207

#	ARTICLE	IF	CITATIONS
19	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 519-528.	9.1	198
20	Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. <i>Haematologica</i> , 2014, 99, 922-929.	3.5	195
21	Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. <i>Blood</i> , 2002, 99, 3524-3529.	1.4	192
22	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2021, 384, 1028-1037.	27.0	187
23	The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome <sup>+</sup> negative acute lymphoblastic leukemia in first and second complete remission. <i>Blood</i> , 2010, 116, 366-374.	1.4	178
24	Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 342-350.	2.8	156
25	A pilot randomized trial comparing CD34 <sup>+</sup> selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2301-2309.	6.7	153
26	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APLM4 study: a non-randomised phase 2 trial. <i>Lancet Haematology</i> , the, 2015, 2, e357-e366.	4.6	133
27	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
28	Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 3500-3507.	1.4	127
29	Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1935-1944.	3.8	125
30	Polymorphism in Human Cytomegalovirus UL40 Impacts on Recognition of Human Leukocyte Antigen-E (HLA-E) by Natural Killer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 8679-8690.	3.4	111
31	Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 1999, 104, 392-396.	2.5	110
32	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. <i>Haematologica</i> , 2013, 98, 1282-1290.	3.5	110
33	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	1.7	107
34	A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies. <i>Clinical Infectious Diseases</i> , 2006, 43, 447-459.	5.8	106
35	Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. <i>Bone Marrow Transplantation</i> , 2006, 38, 567-572.	2.4	96
36	A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. <i>Blood</i> , 2005, 105, 481-488.	1.4	91

#	ARTICLE	IF	CITATIONS
37	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 2034-2041.	7.2	91
38	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	3.5	87
39	Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 601-607.	2.0	86
40	Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2012, 47, 810-816.	2.4	83
41	Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 203-208.	1.4	82
42	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. <i>Lancet Haematology</i> , 2018, 5, e117-e126.	4.6	81
43	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2020, 106, 230-237.	3.5	77
44	Differences between graft product and donor side effects following bone marrow or stem cell donation. <i>Bone Marrow Transplantation</i> , 2003, 32, 873-880.	2.4	76
45	Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. <i>Transplantation</i> , 2004, 77, 587-596.	1.0	76
46	Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 115-121.	2.4	75
47	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
48	How we manage Gaucher Disease in the era of choices. <i>British Journal of Haematology</i> , 2018, 182, 467-480.	2.5	75
49	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	4.1	73
50	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. <i>British Journal of Haematology</i> , 2010, 150, 39-45.	2.5	72
51	Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3835-3843.	3.6	70
52	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 23-26.	2.0	70
53	Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. <i>British Journal of Haematology</i> , 1992, 82, 589-595.	2.5	69
54	BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. <i>Cancer Genetics and Cytogenetics</i> , 2002, 139, 30-33.	1.0	69

#	ARTICLE	IF	CITATIONS
55	The incidence, mortality and timing of <i>Pneumocystis jirovecii</i> pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 573-580.	2.4	68
56	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. <i>Blood Advances</i> , 2018, 2, 2176-2185.	5.2	65
57	The hyper-CVAD rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. <i>Annals of Hematology</i> , 2006, 86, 101-105.	1.8	63
58	Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1021-1025.	2.0	61
59	Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. <i>British Journal of Haematology</i> , 1999, 107, 409-418.	2.5	59
60	Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International <sc>PNH</sc> Registry. <i>Internal Medicine Journal</i> , 2016, 46, 1044-1053.	0.8	59
61	Acute left ventricular failure following melphalan and fludarabine conditioning. <i>Bone Marrow Transplantation</i> , 2001, 28, 101-103.	2.4	58
62	Abnormal cervical cytology in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2001, 28, 393-397.	2.4	51
63	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 253-260.	1.4	51
64	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 122-129.	1.1	51
65	Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries. <i>Bone Marrow Transplantation</i> , 2019, 54, 1179-1188.	2.4	51
66	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
67	The definition of neuronopathic Gaucher disease. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1056-1059.	3.6	51
68	Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2008, 142, 263-272.	2.5	50
69	Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. <i>Haematologica</i> , 2013, 98, 185-192.	3.5	50
70	The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. <i>Blood Reviews</i> , 2006, 20, 71-82.	5.7	48
71	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S15-S18.	2.0	47
72	Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. <i>Bone Marrow Transplantation</i> , 1993, 11, 109-111.	2.4	47

#	ARTICLE	IF	CITATIONS
73	Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Internal Medicine Journal, 2004, 34, 192-200.	0.8	46
74	Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Internal Medicine Journal, 2006, 36, 600-603.	0.8	46
75	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer, 2008, 8, 195.	2.6	46
76	Allogeneic hematopoietic stem cell donation – standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplantation, 2013, 48, 220-225.	2.4	46
77	Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood, 2008, 112, 2120-2128.	1.4	45
78	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal Medicine Journal, 2009, 39, 304-316.	0.8	44
79	Breakthrough <i>Scedosporium prolificans</i> infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transplant Infectious Disease, 2007, 9, 241-243.	1.7	43
80	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biology of Blood and Marrow Transplantation, 2016, 22, 932-940.	2.0	43
81	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 228-241.	2.0	43
82	High-Dose Chemotherapy and Syngeneic Hemopoietic Stem-Cell Transplantation for Severe, Seronegative Rheumatoid Arthritis. Annals of Internal Medicine, 1999, 131, 507.	3.9	42
83	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF. Biology of Blood and Marrow Transplantation, 2006, 12, 603-607.	2.0	40
84	Late Mortality and Relapse Following HLA-Identical Sibling Donor Marrow Transplantation for Chronic Myeloid Leukemia.. Blood, 2008, 112, 3264-3264.	1.4	40
85	Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse. Biology of Blood and Marrow Transplantation, 2009, 15, 1475-1478.	2.0	39
86	Enzyme replacement therapy – drug holiday – Results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells, Molecules, and Diseases, 2011, 46, 107-110.	1.4	39
87	Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplantation, 2017, 52, 671-677.	2.4	39
88	Presenting signs and patient co – variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED – Delphi initiative. Internal Medicine Journal, 2019, 49, 578-591.	0.8	39
89	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. British Journal of Haematology, 2020, 191, 476-485.	2.5	38
90	Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 543-547.	2.0	37

#	ARTICLE	IF	CITATIONS
91	Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
92	One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2019, 134, 2035-2035.	1.4	36
93	Autologous hemopoietic stem cell transplantation. A possible cure for rheumatoid arthritis?. <i>Arthritis and Rheumatism</i> , 1997, 40, 1005-1011.	6.7	35
94	The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. <i>Bone Marrow Transplantation</i> , 2020, 55, 2043-2044.	2.4	35
95	Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. <i>Bone Marrow Transplantation</i> , 2006, 37, 773-779.	2.4	33
96	Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. <i>Internal Medicine Journal</i> , 2008, 38, 468-476.	0.8	31
97	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. <i>Bone Marrow Transplantation</i> , 2019, 54, 402-417.	2.4	31
98	Cisplatin, fludarabine, and cytarabine. <i>Cancer</i> , 2002, 94, 585-593.	4.1	30
99	Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 497-505.	3.0	30
100	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 250-256.	2.5	30
101	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2474-2481.	2.0	30
102	Hematopoietic Stem Cell Transplantation in Australia and New Zealand, 1992-2004. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 905-912.	2.0	29
103	A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 157-163.	2.4	29
104	Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. <i>Annals of Oncology</i> , 2001, 12, 1455-1460.	1.2	28
105	Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. <i>Leukemia</i> , 2006, 20, 404-409.	7.2	28
106	A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 284-291.	2.0	28
107	Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1323-1330.	2.0	27
108	Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. <i>Internal Medicine Journal</i> , 2011, 41, 75-81.	0.8	27

#	ARTICLE	IF	CITATIONS
109	Alloresponses to HLA-DP Detected in the Primary MLR: Correlation with a Single Amino Acid Difference. <i>Human Immunology</i> , 1997, 55, 163-169.	2.4	26
110	The prevalent predicament of relapsed acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 43-8.	2.5	26
111	Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia? a randomized, placebo-controlled, double-blind safety and efficacy study. <i>Annals of Hematology</i> , 2003, 82, 677-683.	1.8	25
112	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 302-308.	2.0	25
113	Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. <i>Bone Marrow Transplantation</i> , 2014, 49, 1016-1021.	2.4	25
114	Screening with Spirometry Is a Useful Predictor of Later Development of Noninfectious Pulmonary Syndromes in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 781-786.	2.0	25
115	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. <i>Internal Medicine Journal</i> , 2015, 45, 1054-1065.	0.8	25
116	Rapid, single-phase extraction of glucosylsphingosine from plasma: A universal screening and monitoring tool. <i>Clinica Chimica Acta</i> , 2015, 450, 6-10.	1.1	25
117	Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon- $\gamma$ for relapsed malignancy after allogeneic bone marrow transplantation. <i>Internal Medicine Journal</i> , 2001, 31, 15-22.	0.8	24
118	A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 560-567.	2.0	24
119	Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. <i>Mycoses</i> , 2007, 50, 24-37.	4.0	24
120	Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. <i>Vaccine</i> , 2021, 39, 7052-7057.	3.8	24
121	Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 727-736.	2.5	23
122	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 435-442.	2.0	22
123	The Journal in 2007. <i>Internal Medicine Journal</i> , 2008, 38, 1-2.	0.8	22
124	An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. <i>Internal Medicine Journal</i> , 2011, 41, 110-120.	0.8	22
125	Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1410-1415.	2.0	22
126	Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. <i>American Journal of Hematology</i> , 2016, 91, 661-665.	4.1	22



#	ARTICLE	IF	CITATIONS
127	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2330-2337.	2.0	22
128	Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 1999, 17, 82-82.	1.6	21
129	Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices. <i>Journal of Hospital Infection</i> , 2014, 88, 48-51.	2.9	21
130	Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 870-877.	2.4	21
131	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2322-2329.	2.0	21
132	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
133	Variability in Determination of Body Weight Used for Dosing Busulphan and Cyclophosphamide in Adult Patients: Results of an International Survey. <i>Leukemia and Lymphoma</i> , 1997, 25, 487-491.	1.3	20
134	Perturbation in the ability of bone marrow stroma from patients with acute myeloid leukemia but not chronic myeloid leukemia to support normal early hematopoietic progenitor cells. <i>Leukemia Research</i> , 1997, 21, 29-36.	0.8	20
135	A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 447-453.	2.4	20
136	Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2006, 37, 923-928.	2.4	20
137	A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. <i>Australian Health Review</i> , 2011, 35, 491.	1.1	20
138	Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. <i>Bone Marrow Transplantation</i> , 2012, 47, 1350-1355.	2.4	20
139	Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 29-34.	1.4	20
140	CD56 <sup>bright</sup> natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. <i>Haematologica</i> , 2017, 102, 1936-1946.	3.5	20
141	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e122-e131.	4.6	20
142	Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. <i>Internal Medicine Journal</i> , 2017, 47, 1026-1034.	0.8	19
143	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.8	19
144	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2372-2377.	2.0	19

#	ARTICLE	IF	CITATIONS
145	The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 701-703.	2.4	18
146	Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient. <i>Transplant Infectious Disease</i> , 2013, 15, E14-9.	1.7	18
147	Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 198.	7.4	18
148	Sequential Transformation of t(8;13)-Related Disease. <i>Acta Haematologica</i> , 2002, 107, 95-97.	1.4	17
149	Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry. <i>Internal Medicine Journal</i> , 2005, 35, 18-27.	0.8	17
150	Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. <i>Bone Marrow Transplantation</i> , 2008, 41, 651-658.	2.4	17
151	Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1102-1108.	2.0	17
152	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	1.3	17
153	Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 232-238.	1.4	17
154	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 7-16.	0.9	17
155	Impact of Gaucher disease on COVID-19. <i>Internal Medicine Journal</i> , 2020, 50, 894-895.	0.8	17
156	Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2011, 52, 179-193.	1.3	16
157	Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2016, 46, 737-741.	0.8	16
158	Atypical retinal microvasculopathy after bone marrow transplantation. <i>Clinical and Experimental Ophthalmology</i> , 2001, 29, 225-229.	2.6	15
159	Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. <i>Internal Medicine Journal</i> , 2019, 49, 152-159.	0.8	15
160	Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. <i>Bone Marrow Transplantation</i> , 2019, 54, 858-866.	2.4	15
161	Special report: Summary of the first meeting of African Blood and Marrow Transplantation (AfBMT) group, Casablanca, Morocco, April 19-21, 2018 held under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT). <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 202-207.	0.9	15
162	High Dose Cytosine Arabinoside is a Major Risk Factor for the Development of Hepatosplenic Candidiasis in Patients with Leukemia. <i>Leukemia and Lymphoma</i> , 1997, 27, 469-474.	1.3	14

#	ARTICLE	IF	CITATIONS
163	The Adaptation of Patients During the Hospitalization Period of Bone Marrow Transplantation. <i>Journal of Clinical Psychology in Medical Settings</i> , 2002, 9, 167-175.	1.4	14
164	Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. <i>Pathology</i> , 2006, 38, 336-342.	0.6	14
165	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1678-1685.	1.6	14
166	Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 117-120.	1.4	14
167	Intraobserver and interobserver variability of the bone marrow burden (BMB) score for the assessment of disease severity in Gaucher disease. Possible impact of reporting experience. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 121-125.	1.4	14
168	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 131-142.	0.9	14
169	Comparison of outcomes of HCT in blast phase of <i>c&lt;i&gt;BCR-ABL1&lt;/i&gt;</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
170	Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. <i>Haematologica</i> , 2020, 106, 64-73.	3.5	14
171	A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. <i>British Journal of Haematology</i> , 2020, 190, e297-e301.	2.5	14
172	Hematological manifestations and complications of Gaucher disease. <i>Expert Review of Hematology</i> , 2021, 14, 347-354.	2.2	14
173	Post-remission therapy for acute myeloid leukaemia with blood-derived stem cell transplantation. Results of a collaborative phase II trial. <i>International Journal of Cell Cloning</i> , 1992, 10, 114-116.	1.6	13
174	The Influence of Induction Chemotherapy Dose and Dose Intensity on the Duration of Remission in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 15, 79-84.	1.3	13
175	Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. <i>British Journal of Haematology</i> , 1997, 96, 635-640.	2.5	13
176	Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: A Prospective Australasian Leukaemia and Lymphoma Group Study. <i>Bone Marrow Transplantation</i> , 2005, 35, 291-298.	2.4	13
177	Late Mortality and Relapse following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 851-855.	2.0	13
178	MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). <i>Annals of Hematology</i> , 2011, 90, 847-849.	1.8	13
179	Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2016, 91, E16-7.	4.1	13
180	Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. <i>Internal Medicine Journal</i> , 2018, 48, 276-285.	0.8	13

#	ARTICLE	IF	CITATIONS
181	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
182	Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 284.	2.7	13
183	Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.. <i>Blood</i> , 2006, 108, 124-124.	1.4	13
184	Sustained remission, possibly cure, of seronegative arthritis after high-dose chemotherapy and syngeneic hematopoietic stem cell transplantation. <i>Arthritis and Rheumatism</i> , 2005, 52, 3322-3322.	6.7	12
185	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
186	Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 14-16.	1.4	12
187	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
188	<sc>COVID</sc>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.8	12
189	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study. <i>Blood</i> , 2011, 118, 117-117.	1.4	12
190	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	1.4	12
191	Allogeneic haemopoietic cell transplants in Australia, 1996 â€ A multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. <i>Bone Marrow Transplantation</i> , 2001, 28, 21-27.	2.4	11
192	Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. <i>Leukemia</i> , 2003, 17, 1916-1917.	7.2	11
193	Cerebral nocardiosis after allogeneic bone marrow transplantation. <i>Internal Medicine Journal</i> , 2004, 34, 698-699.	0.8	11
194	Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1506-1509.	2.4	11
195	Oral chronic graftâ€versusâ€host disease in <sc>A</sc>ustralia: clinical features and challenges in management. <i>Internal Medicine Journal</i> , 2015, 45, 702-710.	0.8	11
196	Activating killerâ€cell immunoglobulinâ€like receptor haplotype influences clinical outcome following HLAâ€matched sibling haematopoietic stem cell transplantation. <i>Hla</i> , 2018, 92, 74-82.	0.6	11
197	Treatable lysosomal storage diseases in the advent of diseaseâ€specific therapy. <i>Internal Medicine Journal</i> , 2020, 50, 5-27.	0.8	11
198	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11

#	ARTICLE	IF	CITATIONS
199	Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. <i>Internal Medicine Journal</i> , 2004, 34, 98-101.	0.8	10
200	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. <i>Blood</i> , 2006, 107, 1733-1735.	1.4	10
201	Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX. <i>Bone Marrow Transplantation</i> , 2010, 45, 1457-1462.	2.4	10
202	Volunteer unrelated donor experience after administration of filgrastim and apheresis for the collection of haemopoietic stem cells: the Australian perspective. <i>Internal Medicine Journal</i> , 2013, 43, 1183-1190.	0.8	10
203	Validating the Allogeneic Stem Cell Transplantation Disease Risk Index. <i>Transplantation</i> , 2015, 99, 128-132.	1.0	10
204	Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 840-844.	2.0	10
205	A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation. <i>Blood</i> , 2013, 122, 4648-4648.	1.4	10
206	Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. <i>Leukemia and Lymphoma</i> , 2011, 52, 1727-1735.	1.3	9
207	The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 722-730.	2.0	9
208	Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-dose cytarabine. <i>European Journal of Haematology</i> , 2018, 101, 174-184.	2.2	9
209	Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1711-1718.	2.0	9
210	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , 2012, 120, 421-421.	1.4	9
211	Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. <i>Blood</i> , 2015, 126, 2863-2863.	1.4	9
212	Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study. <i>Blood</i> , 2016, 128, 2428-2428.	1.4	9
213	A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 645-650.	2.4	8
214	Enzyme replacement therapy for Gaucher disease in Australia. <i>Internal Medicine Journal</i> , 2005, 35, 156-161.	0.8	8
215	How we mobilize haemopoietic stem cells. <i>Internal Medicine Journal</i> , 2011, 41, 588-594.	0.8	8
216	Is a biomarker-based diagnostic strategy for invasive aspergillosis cost effective in high-risk haematology patients?. <i>Medical Mycology</i> , 2017, 55, myw141.	0.7	8

#	ARTICLE	IF	CITATIONS
217	Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2013, 122, 2133-2133.	1.4	8
218	Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab. <i>Blood</i> , 2020, 136, 10-12.	1.4	8
219	Treatment of acute promyelocytic leukaemia relapsing after allogeneic bone marrow transplantation with all-trans-retinoic acid: suppression of the leukaemic clone. <i>British Journal of Haematology</i> , 1991, 79, 331-334.	2.5	7
220	Combined Chemotherapy and Granulocyte Colony-Stimulating Factor (G-CSF) Mobilise Large Numbers of Peripheral Blood Progenitor Cells in Pretreated Patients. <i>Leukemia and Lymphoma</i> , 1994, 15, 91-97.	1.3	7
221	The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 487-493.	0.5	7
222	Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. <i>International Journal of Laboratory Hematology</i> , 2003, 25, 119-125.	0.2	7
223	Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. <i>Internal Medicine Journal</i> , 2004, 34, 431-434.	0.8	7
224	Hepatitis B serological changes following allogeneic bone marrow transplantation. <i>Transplant Infectious Disease</i> , 2013, 15, 98-103.	1.7	7
225	A population-based analysis of the effect of autologous hematopoietic cell transplant in the treatment of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1671-1676.	1.3	7
226	Safety of Living Donation of Hematopoietic Stem Cells. <i>Transplantation</i> , 2016, 100, 1329-1331.	1.0	7
227	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
228	Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies. <i>Blood</i> , 2018, 132, 626-626.	1.4	7
229	Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?. <i>British Journal of Haematology</i> , 2022, 196, 264-265.	2.5	7
230	G-CSF-mobilized peripheral and autologous bone marrow infusion following high dose chemotherapy. <i>International Journal of Cell Cloning</i> , 1992, 10, 71-73.	1.6	6
231	The Journal in 2005. <i>Internal Medicine Journal</i> , 2006, 36, 1-2.	0.8	6
232	The Journal in 2008. <i>Internal Medicine Journal</i> , 2009, 39, 1-4.	0.8	6
233	Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992-2005. <i>Internal Medicine Journal</i> , 2011, 41, 27-34.	0.8	6
234	Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. <i>Leukemia and Lymphoma</i> , 2017, 58, 222-225.	1.3	6

#	ARTICLE	IF	CITATIONS
235	Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1815-1816.	2.0	6
236	Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 175-189.	2.4	6
237	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2252-2261.	2.0	6
238	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
239	Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.. <i>Blood</i> , 2004, 104, 2253-2253.	1.4	6
240	Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry. <i>Blood</i> , 2010, 116, 2241-2241.	1.4	6
241	Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 220-233.	0.8	6
242	Focal lesions on magnetic resonance imaging in aplastic anaemia: Multiple metastases or haemopoietic marrow. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2007, 51, B110-4.	0.6	5
243	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
244	Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.. <i>Blood</i> , 2004, 104, 261-261.	1.4	5
245	Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.. <i>Blood</i> , 2010, 116, 1525-1525.	1.4	5
246	Application of interphase cytogenetics to monitor bone marrow transplants. <i>American Journal of Hematology</i> , 1995, 49, 15-20.	4.1	4
247	Prolonged Disease-Free Survival after Autografting for Chemosensitive Non-Bulky Low Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 39, 283-290.	1.3	4
248	Mentoring in the management of hematological malignancies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 28-34.	1.1	4
249	Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 623-626.	2.5	4
250	Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria. <i>Internal Medicine Journal</i> , 2010, 40, 794-795.	0.8	4
251	Constrictive pericarditis and primary effusion lymphoma following allogeneic BMT for CML. <i>Bone Marrow Transplantation</i> , 2012, 47, 1250-1251.	2.4	4
252	The Journal in 2012. <i>Internal Medicine Journal</i> , 2013, 43, 1-2.	0.8	4

#	ARTICLE	IF	CITATIONS
253	All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand. <i>Bone Marrow Transplantation</i> , 2016, 51, 1400-1403.	2.4	4
254	Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 147-152.	2.0	4
255	Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 169-174.	2.0	4
256	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. <i>Bone Marrow Transplantation</i> , 2020, 55, 698-707.	2.4	4
257	A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics. <i>Blood</i> , 2018, 132, 627-627.	1.4	4
258	A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2018, 132, 2330-2330.	1.4	4
259	A Multicentre, Double-Blind, Randomized, Phase 2 Trial Comparing Pegfilgrastim with Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML).. <i>Blood</i> , 2004, 104, 866-866.	1.4	4
260	Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.. <i>Blood</i> , 2007, 110, 1846-1846.	1.4	4
261	Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2010, 116, 4237-4237.	1.4	4
262	Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study. <i>Blood</i> , 2011, 118, 5050-5050.	1.4	4
263	Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. <i>European Journal of Haematology</i> , 2022, 108, 391-402.	2.2	4
264	When to transplant in myelodysplasia? Markov helps. <i>Blood</i> , 2004, 104, 304-305.	1.4	3
265	Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 896-901.	1.3	3
266	Flow-cytometric minimal residual disease monitoring for chronic lymphocytic leukemia in the post-allogeneic transplant period. <i>Leukemia and Lymphoma</i> , 2011, 52, 2185-2187.	1.3	3
267	The Journal in 2011. <i>Internal Medicine Journal</i> , 2012, 42, 1-2.	0.8	3
268	Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 566-572.	2.4	3
269	Recent advances and future challenges in Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 9-13.	1.4	3
270	Rapid intravenous infusion of velaglucerase- $\alpha$ in adults with type 1 Gaucher disease. <i>American Journal of Hematology</i> , 2018, 93, E246-E248.	4.1	3



#	ARTICLE	IF	CITATIONS
271	COVID-19: looking forward. Internal Medicine Journal, 2020, 50, 657-657.	0.8	3
272	Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2007, 110, 3672-3672.	1.4	3
273	A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. Blood, 2013, 122, 709-709.	1.4	3
274	Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study. Blood, 2014, 124, 3276-3276.	1.4	3
275	Hematopoietic Stem Cell Transplantation: a Global Perspective From the Worldwide Network of Blood and Marrow Transplantation.. Blood, 2009, 114, 809-809.	1.4	3
276	Oromandibular parafunction in chronic graft-versus-host disease: novel association and treatment approach. Internal Medicine Journal, 2021, 51, 1950-1953.	0.8	3
277	The Journal in 2004. Internal Medicine Journal, 2005, 35, 1-2.	0.8	2
278	Relapsed blastic natural killer cell leukaemia with splenic rupture. British Journal of Haematology, 2006, 135, 2-2.	2.5	2
279	Classifying the additional morbidities of Gaucher disease. Blood Cells, Molecules, and Diseases, 2018, 68, 209-210.	1.4	2
280	The Journal in 2018. Internal Medicine Journal, 2019, 49, 7-8.	0.8	2
281	Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 185-188.	1.3	2
282	Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 35-37.	1.4	2
283	Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study. Blood, 2011, 118, 2102-2102.	1.4	2
284	Global Trends in Hematopoietic Cell Transplantation.. Blood, 2012, 120, 3143-3143.	1.4	2
285	Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia â€” a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse. Blood, 2014, 124, 1927-1927.	1.4	2
286	Causes and Effects of Methotrexate Dose Alterations in Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 2460-2460.	1.4	2
287	Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2014, 124, 4393-4393.	1.4	2
288	Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes. Current Oncology, 2020, 27, 596-606.	2.2	2

#	ARTICLE	IF	CITATIONS
289	Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study. <i>Blood</i> , 2016, 128, 2000-2000.	1.4	2
290	Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316). <i>Blood</i> , 2018, 132, 205-205.	1.4	2
291	Combination prophylactic immunosuppression in bone marrow transplantation. <i>Transplantation Proceedings</i> , 1989, 21, 3011-2.	0.6	2
292	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 455-462.	1.2	2
293	Chronic myeloid leukaemia treated by allogeneic bone marrow transplantation from histocompatible sibling donors "an invariably fatal malignancy rendered highly curable. <i>Australian and New Zealand Journal of Medicine</i> , 1991, 21, 408-413.	0.5	1
294	Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis. <i>Internal Medicine Journal</i> , 2004, 34, 66-69.	0.8	1
295	Democracy or dictatorship at the bedside?. <i>Internal Medicine Journal</i> , 2006, 36, 275-275.	0.8	1
296	Harvesting haemopoietic stem cells for future use: rainy days, real or imagined?. <i>Internal Medicine Journal</i> , 2008, 38, 227-228.	0.8	1
297	The substrate is down: is the IV out?. <i>Blood</i> , 2010, 116, 860-861.	1.4	1
298	Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 9-13.	1.1	1
299	The Journal in 2017. <i>Internal Medicine Journal</i> , 2018, 48, 7-8.	0.8	1
300	Is there no place like home for an allogeneic stem cell transplant?. <i>Bone Marrow Transplantation</i> , 2020, 55, 855-856.	2.4	1
301	Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement. <i>Blood</i> , 2020, 136, 32-33.	1.4	1
302	Activated Recombinant Factor VII (rFVIIa/NovoSeven <sup>®</sup> ) in the Treatment of Bleeding Complications Following Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2004, 104, 1135-1135.	1.4	1
303	Long Term Follow-Up of Patients with Chronic Myeloid Leukemia Receiving BuCy2 as Preparation for Allogeneic Transplantation.. <i>Blood</i> , 2006, 108, 3364-3364.	1.4	1
304	Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.. <i>Blood</i> , 2007, 110, 4381-4381.	1.4	1
305	The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009, 114, 1749-1749.	1.4	1
306	Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2012, 120, 1260-1260.	1.4	1

#	ARTICLE	IF	CITATIONS
307	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 2021, 51, 1707-1712.	0.8	1
308	Mannose-Binding Lectin Status Is Associated with Risk of Major Infection Following Myeloablative Sibling Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2928-2928.	1.4	1
309	Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap. Blood, 2011, 118, 1016-1016.	1.4	1
310	A Local Experience of Pregnancy Outcomes in Sickle Cell Disease and Red Cell Exchange. Blood, 2018, 132, 4920-4920.	1.4	1
311	We must grow the Australian Bone Marrow Donor Registry. Internal Medicine Journal, 2021, 51, 1771-1772.	0.8	1
312	Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study. Blood, 2020, 136, 26-27.	1.4	1
313	Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion. Clinical Advances in Hematology and Oncology, 2012, 10, 1-16.	0.3	1
314	Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant. Bone Marrow Transplantation, 2022, , .	2.4	1
315	Addressing Ethical and Procedural Principles for Unrelated Allogeneic Hematopoietic Progenitor Cell Donation in a Changing Medical Environment. Biology of Blood and Marrow Transplantation, 2018, 24, 887-894.	2.0	1
316	Fat fraction quantification of bone marrow in the lumbar spine using the LiverLab assessment tool in healthy adult volunteers and patients with Gaucher Disease. Internal Medicine Journal, 0, , .	0.8	1
317	RFPLY. Australian and New Zealand Journal of Medicine, 1983, 13, 643-643.	0.5	0
318	Small molecule: large hopes. Internal Medicine Journal, 2001, 31, 382-383.	0.8	0
319	The Journal in 2006. Internal Medicine Journal, 2007, 37, 1-2.	0.8	0
320	Enzyme replacement therapy for Gaucher disease in Australia. Acta Paediatrica, International Journal of Paediatrics, 2007, 91, 153-153.	1.5	0
321	The Journal in 2009. Internal Medicine Journal, 2010, 40, 1-2.	0.8	0
322	Virtual everything. Internal Medicine Journal, 2010, 40, 473-473.	0.8	0
323	The Journal in 2010. Internal Medicine Journal, 2011, 41, 1-2.	0.8	0
324	Could renal impairment be a positive predictor of outcome in autografts for myeloma?. Bone Marrow Transplantation, 2016, 51, 1305-1306.	2.4	0

#	ARTICLE	IF	CITATIONS
325	Uncommon diagnoses do occur. <i>Lancet, The</i> , 2016, 388, 1128.	13.7	0
326	The Journal in 2016. <i>Internal Medicine Journal</i> , 2017, 47, 5-6.	0.8	0
327	Preface to the special issue on Gaucher disease 2017. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 1-2.	1.4	0
328	2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S744-S744.	0.9	0
329	Selected state of the art research in internal medicine, 2017. <i>Internal Medicine Journal</i> , 2018, 48, 619-623.	0.8	0
330	Effect of donor age on adult unrelated donor haemopoietic cell transplant outcome: the Australian experience. <i>Internal Medicine Journal</i> , 2022, 52, 57-62.	0.8	0
331	The Journal in 2019. <i>Internal Medicine Journal</i> , 2020, 50, 9-10.	0.8	0
332	The Journal in 2020. <i>Internal Medicine Journal</i> , 2021, 51, 5-6.	0.8	0
333	Wine & Blood. An Unlikely Pairing By Shaun R.McCann. Moldova: Eliva Press; 2020. 104 pp. (Paperback). ISBN 978â€9975â€3417â€7â€6. <i>Internal Medicine Journal</i> , 2021, 51, 157-157.	0.8	0
334	Clinical ethics resources from the Royal Australasian College of Physicians. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 751-751.	0.8	0
335	<scp>COVID</scp>â€19: looking backward. <i>Internal Medicine Journal</i> , 2021, 51, 1203-1204.	0.8	0
336	A Matched Pair Retrospective Comparison of Adult Unrelated and Sibling Donor Allogeneic Transplantation for AML. <i>Blood</i> , 2004, 104, 5173-5173.	1.4	0
337	Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.. <i>Blood</i> , 2004, 104, 2262-2262.	1.4	0
338	Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cyto-reduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic Lymphatic Leukemia (CLL).. <i>Blood</i> , 2004, 104, 5045-5045.	1.4	0
339	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.. <i>Blood</i> , 2005, 106, 1970-1970.	1.4	0
340	Long-Term Follow-Up of Treatment for Acute Myeloid Leukemia with Allogeneic Hematopoietic Cell Transplantation Using BuCy2 as Preparation.. <i>Blood</i> , 2006, 108, 3370-3370.	1.4	0
341	Extended TNF Genotyping Identifies TNF -857T as a Risk Factor for Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 39-39.	1.4	0
342	Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5115-5115.	1.4	0

#	ARTICLE	IF	CITATIONS
343	Risk Factors for Blood Product Usage Following Sibling Allogeneic Haemopoietic Stem Cell Transplantation (allo-HCT).. Blood, 2007, 110, 2909-2909.	1.4	0
344	Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma.. Blood, 2008, 112, 2188-2188.	1.4	0
345	Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.. Blood, 2008, 112, 2172-2172.	1.4	0
346	A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2009, 114, 3007-3007.	1.4	0
347	Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998â€“2006: factors associated with improved survival outcome. Leukemia and Lymphoma, 0, , 1-9.	1.3	0
348	Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations. Blood, 2013, 122, 2143-2143.	1.4	0
349	Intravenous Immunoglobulin Post Allogeneic Stem Cell Transplantation Is Associated with Lower Levels of CMV Reactivation. Blood, 2014, 124, 2482-2482.	1.4	0
350	Choice of Conditioning Regimen Influences Risk of Thymoglobulin Infusion Reactions in Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 5840-5840.	1.4	0
351	Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. Blood, 2015, 126, 3961-3961.	1.4	0
352	Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia. Blood, 2015, 126, 2599-2599.	1.4	0
353	Real-World Use of Therapeutic Anticoagulation in Patients with Paroxysmal Nocturnal Hemoglobinuria. Results of a Survey of Physicians in Australia. Blood, 2015, 126, 4537-4537.	1.4	0
354	Patients with Paroxysmal Nocturnal Hemoglobinuria and Hemolysis Demonstrate More Frequent Disease-Related Features Than Those without Hemolysis, but Similar Proportions Experience Thromboembolism. Blood, 2015, 126, 3339-3339.	1.4	0
355	Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Blood, 2015, 126, 3340-3340.	1.4	0
356	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. Blood, 2016, 128, 338-338.	1.4	0
357	Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab. Blood, 2018, 132, 625-625.	1.4	0
358	The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study. Blood, 2019, 134, 412-412.	1.4	0
359	Longitudinal Genomic Characterization Using Cell-Free DNA in Patients with Idiopathic Aplastic Anemia. Blood, 2020, 136, 5-6.	1.4	0
360	Efficacy and Safety of Ravulizumab in Older Patients Aged &gt;65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies. Blood, 2020, 136, 42-43.	1.4	0

#	ARTICLE	IF	CITATIONS
361	The Journal in 2021. Internal Medicine Journal, 2022, 52, 5-6.	0.8	0
362	Chronic myeloid leukemia treated by allogeneic bone marrow transplantation. Transplantation Proceedings, 1992, 24, 181-2.	0.6	0
363	Current thinking in the management of leukaemia. Australian Family Physician, 1994, 23, 1500-5.	0.5	0
364	Allogeneic peripheral blood progenitor cell transplantation—the Australian experience. Bone Marrow Transplantation, 1996, 17 Suppl 2, S51-3.	2.4	0
365	HLA-identical sibling peripheral blood cell transplants. The Australian experience and preliminary results of a randomised study. Bone Marrow Transplantation, 1998, 21 Suppl 3, S57-8.	2.4	0
366	Predictors and Outcomes of Dose Reduction of Methotrexate and Cyclosporin <scp>Graftâ€Versusâ€Hostâ€Disease</scp> Prophylaxis Following Allogeneic Haematopoietic Cell Transplantation. Internal Medicine Journal, 0, , .	0.8	0